

Resource Summary Report

Generated by [RRID](#) on Sep 3, 2026

U-CH1

RRID:CVCL_4988

Type: Cell Line

Proper Citation

RRID:CVCL_4988

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_4988

Proper Citation: RRID:CVCL_4988

Description: Cell line U-CH1 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Sacral chordoma

Defining Citation: [PMID:11579460](#), [PMID:20461036](#), [PMID:21253487](#), [PMID:23325432](#), [PMID:26183925](#), [PMID:27102572](#), [PMID:28515451](#), [PMID:28606919](#), [PMID:28835717](#)

Comments: Part of: ENCODE project common cell types; tier 3., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: U-CH1

Synonyms: UCH-1, UCH1

Cross References: EFO:EFO_0004389, ATCC:CRL-3217, cancercellines:CVCL_4988, Cosmic:2663857, DepMap:ACH-002335, DSMZ:ACC-748, DSMZCellDive:ACC-748, ENCODE:ENCBS267AAA, GDSC:1503374, GEO:GSM1673845, GEO:GSM1673846, PharmacDB:UCH1_1626_2019, PubChem_Cell_line:CVCL_4988, Wikidata:Q54973610

ID: CVCL_4988

Record Creation Time: 20220427T221639+0000

Record Last Update: 20260904T015835+0000

Ratings and Alerts

No rating or validation information has been found for U-CH1.

No alerts have been found for U-CH1.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 3 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Nelson BE, et al. (2025) Phase Ib Study of Pembrolizumab in Combination with Intratumoral Injection of Clostridium novyi-NT in Patients with Advanced Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research, 31(18), 3864.

Cottone L, et al. (2025) ATF4-mediated stress response as a therapeutic vulnerability in chordoma. Molecular oncology.

Kawaai K, et al. (2024) Chordoma cells possess bone-dissolving activity at the bone invasion front. Cellular oncology (Dordrecht, Netherlands), 47(5), 1663.